Across TCGA pan-cancer cohorts, MDS2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MDS2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MDS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MDS2 expression acts as an unfavorable survival marker.

LUAD and UCEC are the cancer types where MDS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.313	0.812	.015	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MDS2 tumor-vs-normal RNA expression · all MDS2 data types